Oxford University group and the British-Swedish pharmaceutical company AstraZeneca, are right in there with the Moderna Group which is starting wide numbered testing of their vaccine with tens of thousands of subjects…..
The American Federal government has purchased millions of vaccine doses from both lead vaccine companies ….
While the trails going forward will be ‘experimental’….
From now thru these trials American’s will have access to over a hundred thousand vaccine treatments….
But with hopes soaring that a number of vaccines will soon emerge to quiet the global pandemic, Britain and the United States have already ordered millions of doses of the Oxford vaccine, while the Chinese military is preparing to deploy its candidate if it proves effective in larger studies.
The Oxford vaccine is named ChAdOx1 nCoV-19 and was made from a weakened and nonreplicating version of a common coldvirus, an adenovirus. The vaccine has been engineered to express a bit of the coronavirus that produces the spike protein that the virus uses to enter and infect human cells.
An editorial in the Lancet warned, “The race for a vaccine moves fast, as the need for a solution is evident, but we cannot forget that safety is of the highest importance.”
Infectious-disease experts caution that vaccines must be widely administered to protect the general population, and in an era of widespread skepticism, and even overt hostility toward research and scientists, any vaccine that underperforms or causes serious side effects will set back the effort.
The Oxford candidate is one of 23 vaccines now being tested in human trials, according to a running tally kept by the World Health Organization…..
Another group’s vaccine progress….
A small study of hospitalized Covid-19 patients in Britain has identified a promising new treatment for the illness, a British biotechnology company said on Monday, with initial results showing that an inhaled form of a commonly available drug can reduce the odds of patients requiring intensive care.
But the trial, which sent shares of the company, Synairgen, soaring, caused some consternation among scientists, who demanded to see more detailed data and faulted the company for failing to make clear exactly how helpful the drug was or how long its benefits lasted.
Synairgen, founded by researchers at the University of Southampton, said that an inhaled form of interferon beta, a protein that the body produces in response to viral infections, could significantly reduce the odds of patients becoming severely ill and accelerate their recoveries.
The results, while significant, are far from certain. The double-blind trial involved only 101 patients, Synairgen said, making it difficult to know for certain how beneficial the drug was or how it affected patients differently. Scientists stressed the need for more details on how the study had been conducted and a more complete set of results from the trial, which has not yet been peer reviewed or published….